miRNA生物合成相关基因的遗传变异与胃癌患者生存的关系  

Genetic Variants in MiRNA Machinery Genes Associated with Prognosis of Gastric Cancer Patients

作　　者：廖瑜露[1] 李俊[1] 万以叶[1] 彭丽香[1] 廖瑜倩[1] LIAO Yulu;LI Jun;WAN Yiye(Jiangxi Cancer Hospital,Nanchang,33002)

机构地区：[1]江西省肿瘤医院,330029

出　　处：《实用癌症杂志》2018年第5期745-748,共4页The Practical Journal of Cancer

摘　　要：目的研究miRNA生物合成相关基因的遗传变异与胃癌患者生存的关系。方法 96例接受奥沙利铂联合氟尿嘧啶类药物术后辅助化疗的Ⅰ~Ⅲ期胃癌患者,分析DICER rs13078,DICER rs3742330,RAN rs14035,XPO5 rs2257082,XPO5 rs11077遗传变异与患者无病生存期(DFS)和总生存期(OS)的相关性。结果全组患者2年DFS为60.5%,3年OS为73.2%。淋巴结转移患者的3年OS显著低于无淋巴结转移患者,分别为63.7%和88.6%(P=0.017)。临床分期与3年OS显著相关,Ⅰ、Ⅱ和Ⅲ期患者分别为100.0%、87.9%和56.9%(P=0.020)。携带XPO5 rs11077 AC基因型患者的3年OS显著低于AA基因型患者,分别为64.8%和74.7%(P=0.029)。多因素预后分析显示,淋巴结状态及XPO5 rs11077遗传变异为独立预后因素。结论 XPO5 rs11077遗传变异可能与胃癌患者预后相关。Objective To explore the relationship between genetic variants in miRNA machinery genes and outcomes in gastric cancer patients. Methods 96 patients with stage I-III gastric cancer treated with radical gastrectomy and adjuvant chemotherapy of oxaliplatin and fluorouracils were analyzed. Mass ARRAY MALDI-TOF system was used to determine the genotypes. Results The 2-year DFS rate was 60. 5% and the 3-year OS rate was 73. 2%. The 3-year OS was significantly different in patients with or without lymph node metastasis（63. 7% vs 88. 6%,P = 0. 017） and in patients with stage I-III disease（100. 0%,87. 9%and 56. 9%,P = 0. 020. The 3-year OS for XPO5 rs11077 AA carriers was significantly higher than AC carriers（ 74. 7% vs64. 8%,P = 0. 029）. After the multi-variants＇ cox regression analysis,lymph node status and XPO5 rs11077 were found to be independent prognostic factors for these patients. Conclusion XPO5 rs11077 could be associated with prognosis of gastric cancer patients treated with oxaliplatin and fluorouracils after surgical resection.

关 键 词：MIRNA 遗传变异 胃癌 预后 

分 类 号：R735.2[医药卫生—肿瘤]